Gaithersburg, United States
miRecule, Inc., a promising player in the RNA Therapeutics domain, is pioneering first-in-class RNA-based therapies, focusing on conditions such as Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Established in 2016, this United States-based startup operates within the Biopharma, Biotechnology, and Health Care industries.
Leading its innovative approach, the company's proprietary DREAmiR™ platform leverages genomic and outcome data from a significant patient base to pinpoint critical genetic anomalies. This process facilitates the development of bespoke RNA therapeutics tailored to address specific genetic faults, epitomizing their commitment to precision medicine.
In terms of funding, miRecule, Inc. secured a $5.70M Seed Round on 28 May 2021, with backing from prominent investors such as Alexandria Venture Investments, Boutique Venture Partners, Pathway Bioventures, Alumni Ventures, University System of Maryland Momentum Fund, and the FSHD Society.
